Compare AAON & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAON | RVMD |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.5B |
| IPO Year | N/A | 2020 |
| Metric | AAON | RVMD |
|---|---|---|
| Price | $80.87 | $79.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $104.00 | $77.11 |
| AVG Volume (30 Days) | 862.0K | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,315,577,000.00 | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $12.34 | $714.50 |
| P/E Ratio | $68.25 | ★ N/A |
| Revenue Growth | ★ 8.77 | N/A |
| 52 Week Low | $62.00 | $29.17 |
| 52 Week High | $137.90 | $81.49 |
| Indicator | AAON | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 73.98 |
| Support Level | $79.65 | $77.54 |
| Resistance Level | $84.59 | $81.49 |
| Average True Range (ATR) | 3.66 | 2.50 |
| MACD | -0.90 | -0.47 |
| Stochastic Oscillator | 3.15 | 77.20 |
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BASX. It generates the majority of its revenue from the AAON Oklahoma segment which engineers, manufactures, and sells, semi-custom, and custom HVAC systems, designs and manufactures control solutions, and sells retail parts to customers through retail part stores and online.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.